Stanford EB Publications

2019:

Eichstadt S, Barriga M, Ponakala A, Teng C, Nguyen NT, Siprashvili Z, Nazaroff J, Gorell ES, Chiou AS, Taylor L, Khuu P, Keene DR, Rieger K, Khosla RK, Furukawa LK, Lorenz HP, Marinkovich MP, Tang JY. Phase 1/2a Clinical Trial of Gene Corrected Autologous Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa. JCI Insight. Oct. 2019. 4(19):pii130554. Link to PubMed.

Chiou AS, Choi S, Barriga M, Dutt-Singkh Y, Solis DC, Nazaroff J, Bailey-Healy I, Li S, Shu K, Joing M, Kwon P, Tang JY. Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial. J Am Acad Dermatol. In press. Link to PubMed.

Feinstein JA, Jambal P, Peoples K, Lucky AW, Khuu P, Tang JY, Lara-Corrales I, Pope E, Wiss K, Hook KP, Levin LE, Morel KD, Paller AS, McCuaig CC, Powell J, Eichenfeld LF, Price H, Levy ML, Schachner LA, Browning JC, Bayliss S, Jahnke M, Shwayder T, Glick SA, Bruckner AL. Assessment of the Timing of Milestone Clinical Events in Patients with Epidermolysis Bullosa from North America. JAMA Dermatology. Feb. 2019. 155(2):196-203. Link to PubMed.

Marinkovich M, Tang JY. Gene Therapy for Epidermolysis Bullosa. J Invest Dermatol. 2019; 139(6):1221-26. Link to PubMed

Li L, Wang Y, Torkelson JL, Shankar G, Pattison JM, Zhen HH, Fang F, Duran Z, Xin J, Gaddam S, Melo SP, Piekos SN, Li J, Liaw EJ, Chen L, Li R, Wernig M, Wong WH, Chang HY, Oro AE. TFAP2C- and p63-Dependent Networks Sequentially Rearrange Chromatin Landscapes to Drive Human Epidermal Lineage Commitment. Cell Stem Cell. Feb. 2019. 24(2):271-284. Link to PubMed.

2018:

Nazaroff J, Manoukian M, Barriga M, Lane A, Marinkovich MP, Tang JY. Measurement of Skin Adhesion in Recessive Dystrophic Epidermolysis Bullosa Patients. J Am Acad Dermatol. Aug. 2018. S0190-9622(18)32336-3. Link to PubMed

Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-Initiated use of Topical Cannabidiol Oil for Epidermolysis Bullosa. Pediatr Dermatol. Jul. 2018. 35(4): e224-e227. Link to PubMed

Marinkovich MP. A new deletion mutation sheds light on laminin-332 biology. Br J Dermatol. Jun. 2018. 178(6):1245. Link to PubMed.

2017:

Nazaroff J, Solis D, Barriga M, Dutt-Singkh Y, Shufeng L, Marinkovich MP, Tang JY. Validity and Accuracy of a Mobile Phone Application for the Assessment of Wounds in Recessive Dystrophic Epidermolysis Bullosa. J Am Acad Dermatol. Nov. 2017. S0190-9622(17)32688-9. Link to PubMed

Fogel AL, Sarin KY, Teng JMC. Genetic diseases associated with an increased risk of skin cancer development in childhood. Curr Opin Pediatr. Aug. 2017. 29(4):426-433. Link to PubMed.

Heinecke G, Marinkovich MP, Rieger KE. Intraepidermal Type VII Collagen by Immunofluorescence Mapping: A Specific Finding for Bullous Dermolysis of the Newborn. Pediatr Dermatol. May 2017. 34(3):308-314. Link to PubMed.

2016:

Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, Lorenz HP, Leung TH, Keene DR, Rieger KE, Khavari P, Lane AT, Tang JY, Marinkovich MP. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients with Recessive Dystrophic Epidermolysis Bullosa.  JAMA.  Nov. 2016. 316(17): 1808-1817. Link to PubMed

Cohn HI, Teng JM. Advancement in management of epidermolysis bullosa. Curr Opin Pediatr. Aug. 2016. 28(4): 507-16. Link to PubMed.

Teng JM. Pediatric dermatology: advancement in management and targeted therapy. Curr Opin Pediatr. Aug. 2016. 28(4): 454-5. Link to PubMed.

2015:

Gorell ES, Nguyen N, Siprashvili Z, Marinkovich MP, Lane AT. Characterization of dystrophic epidermolysis bullosa patients for collagen VII therapy. Br J Dermatol.  Sept. 2015. 173(3): 821-823. Link to PubMed

Danial C, Adeduntan R, Gorell ES, Lucky A, Paller A, Bruckner A, Pope E, Morel K, Levy M, Li S, Gilmore E, Lane AT. Evaluation of treatments for pruritus in epidermolysis bullosa. Pediatr Dermatol. Sept. 2015. 32(5): 628-634. Link to PubMed

Gorell ES, Leung TH, Khuu P, Lane AT. Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol. Mar. 2015. 32(2):220-225. Link to PubMed

Danial C, Adeduntan R, Gorell ES, Lucky A, Paller A, Bruckner A, Pope E, Morel K, Levy M, Li S, Gilmore E, Lane AT. Prevalence and characterization of pruritus in epidermolysis bullosa.  Pediatr Dermatol. Jan. 2015. 32(1): 53-59. Link to PubMed.  

2014:

Sebastiano, V, Zhen HH, Derafshi, BH, Bashkirova, L, Melo, S, Wang, P, Leung, T, Siprashvili, Tichy, A., Li,J, Ameen M., Hawkins, J., Lee, S., Li, L, Bauer, G., Lisowski, Kay, M., Kim, SK, Lane, AT, Wernig, M. and Oro, AE (2014) Corrected Induced Pleuripotent Stem Cell Based Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa, Sci Transl Med 6:264-7.  Link to PubMed.

Melo SP, Lisowski L, Bashkirova E, Zhen HH, Chu K, Keene DR, Marinkovich MP, Kay MA, Oro AE. Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant. Mol Ther. Apr. 2014. 22(4):725-33. Link to PubMed.

Gorell E, Nguyen N, Lane A, Siprashvili Z. Gene therapy for skin diseases. Cold Spring Harb Perspect Med. Apr. 2014. 4(4):a015149. Link to PubMed.

2013:

Fortuna G, Lozada-Nur F. Pollio A, Aria M, Cepeda-Valdes R, Marinkovich MP, Bruckner AL, Salas-Alanis JC. Patterns of oral mucosa lesions in patients with epidermolysis bullosa: comparison and agreement between oral medicine and dermatology. J Oral Pathol Med. Nov. 2013. 42(10):733-40. Link to PubMed.

Berk DR, Jazayeri L, Marinkovich MP, Sundram UN, Bruckner AL. Diagnosing epidermolysis bullosa type and subtype in infancy using immunofluorescence microscopy: the Stanford experience. Pediatr Dermatol. Mar.-Apr. 2013. 30(2):226-33. Link to PubMed.

Fortuna G, Chainani-Wu N, Lozada-Nur F, Aria M, Cepeda-Valdes R, Pollio A, Marinkovich MP, Martinez-Salazar AE, Mignogna MD, Bruckner AL, Salas-Alanis JC. Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score: a multicenter development and reliability assessment. J Am Acad Dermatol. Jan. 2013. 68(1):83-92. Link to PubMed.

2012:

Chamcheu JC, Wood GS, Siddiqui IA, Syed DN, Adhami VM, Teng JM, Mukhtar H. Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. Exp Dermatol. Jul 2012. 21(7): 481-9. Link to PubMed.

2011:

Bruckner AL, Bedocs LA, Keiser E, Tang JY, Doernbrack C, Arbuckle HA, Berman S, Kent K, Bachrach LK. Correlates of low bone mass in children with generalized forms of epidermolysis bullosa. J Am Acad Dermatol. Nov. 2011. 65(5):1001-9. Link to PubMed.

Fu T, Lingala B, Kent K, Bachrach LK, Bruckner AL. Patterns of bone mineral acquisition in children with epidermolysis bullosa: a longitudinal study. Br J Dermatol. Nov. 2011. 165(5):1081-6. Link to PubMed.

Hashmi S, Marinkovich MP. Molecular organization of the basement membrane zone. Clin Dermatol. Jul.-Aug. 2011. 29(4):398-411. Link to PubMed.

Gorell ES, Tichy AL, Lane AT. Successful investigational new drug preparation without reinventing the wheel. J Invest Dermatol. May 2011. 131(5):996-8. Link to PubMed.

2010:

Siprashvili Z, Nguyen NT, Bezchinsky MY, Marinkovich MP, Lane AT, Khavari PA. Long term type VII collagen restoration to human epidermolysis bullosa skin tissue. Hum Gene Ther. Oct. 2010. 21(10):1299-310. Link to PubMed.

Sakai N, Waterman EA, Nguyen NT, Keene DR, Marinkovich MP. Observations of skin grafts derived from keratinocytes expressing selectively engineered mutant laminin-332 molecules. J Invest Dermatol. Aug. 2010. 130(8):2147-50. Link to PubMed.